Literature DB >> 2528316

Decrease of suppressor inducer (CD4+2H4+) T cells in multiple sclerosis cerebrospinal fluid.

M Chofflon1, H L Weiner, C Morimoto, D A Hafler.   

Abstract

T-lymphocytes in the cerebrospinal fluid of patients with multiple sclerosis are predominantly CD4+ (inducer) as opposed to CD8+ (suppressor/cytotoxic) T cells. The CD4+ lymphocytes can be subdivided into populations that express high densities of the CDw29 (4B4) determinant and have helper inducer function or express high densities of CD45R (2H4) determinant and have suppressor inducer function. In the present study, we characterized the nature of these CD4+ T cells in the cerebrospinal fluid of patients with multiple sclerosis by performing flow cytometric analysis on paired samples of blood and cerebrospinal fluid. There were significantly lower percentages of CD4+2H4+ T cells in the cerebrospinal fluid than in the peripheral blood (p = 0.001, paired t test). In contrast, there were increased percentages of helper inducer (CD4+4B4+) T cells in the cerebrospinal fluid (p = 0.001, paired t test), compared with the peripheral blood. Analysis of subjects with other inflammatory disorders of the central nervous system did not show significant decreases in CD4+2H4+ T cells in cerebrospinal fluid, though in some, decreases were also observed. These results indicate that the CD4+ T cells in the cerebrospinal fluid of patients with multiple sclerosis are predominantly helper inducer, as opposed to suppressor inducer T cells, and that the relative decrease of suppressor inducer cells in the peripheral blood of multiple sclerosis patients is not due to their migration to the cerebrospinal fluid. Furthermore, the increased numbers of helper inducer cells in the cerebrospinal fluid may contribute to local autoimmune processes in the central nervous system compartment of multiple sclerosis patients.

Entities:  

Mesh:

Year:  1989        PMID: 2528316     DOI: 10.1002/ana.410250512

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  8 in total

1.  Decrease of CD4+CD45+ T-cells in chronic-progressive multiple sclerosis.

Authors:  M Zaffaroni; S Rossini; A Ghezzi; R Parma; C L Cazzullo
Journal:  J Neurol       Date:  1990-02       Impact factor: 4.849

2.  CD4+ lymphocyte subsets in the cerebrospinal fluid of multiple sclerosis and non-inflammatory neurological diseases.

Authors:  M Zaffaroni; L Gallo; A Ghezzi; C L Cazzullo
Journal:  J Neurol       Date:  1991-07       Impact factor: 4.849

3.  Abnormalities within CD4 and CD8 T lymphocytes subsets in type 1 (insulin-dependent) diabetes.

Authors:  J Ilonen; H M Surcel; M L Käär
Journal:  Clin Exp Immunol       Date:  1991-08       Impact factor: 4.330

Review 4.  Multiple sclerosis: a unique immunopathological syndrome of the central nervous system.

Authors:  S F Hunter; M Rodriguez
Journal:  Springer Semin Immunopathol       Date:  1995

5.  Evidence for a missed signal to the CD8+ cells in CSF of multiple sclerosis patients.

Authors:  M Saresella; A Grope; L Speciale; R Mancuso; R De Benedictis; D Caputo; P Ferrante
Journal:  Ital J Neurol Sci       Date:  1995-10

6.  Correlation of serum IL-13 and IL-5 levels with clinical response to Glatiramer acetate in patients with multiple sclerosis.

Authors:  E Wiesemann; J Klatt; C Wenzel; F Heidenreich; A Windhagen
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

7.  Presence of T-cell subset abnormalities in newly diagnosed cases of multiple sclerosis and relationship with short-term clinical activity.

Authors:  M Eoli; M Ferrarini; A Dufour; S Heltaj; L Bevilacqua; G Comi; V Cosi; G Filippini; V Martinelli; C Milanese
Journal:  J Neurol       Date:  1993-02       Impact factor: 4.849

Review 8.  Multiple Sclerosis and Obesity: Possible Roles of Adipokines.

Authors:  José de Jesús Guerrero-García; Lucrecia Carrera-Quintanar; Rocío Ivette López-Roa; Ana Laura Márquez-Aguirre; Argelia Esperanza Rojas-Mayorquín; Daniel Ortuño-Sahagún
Journal:  Mediators Inflamm       Date:  2016-09-18       Impact factor: 4.711

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.